loading page

The dilemma of Tocilizumab therapy for a patient with critical COVID-19 disease and neutropenia: Case report and review of the literature
  • +6
  • Ahmad Al Bishawi,
  • Shiema Abdalla,
  • Marwa Askar,
  • Wael Kanjo,
  • Amal Sameer,
  • Gihan Mustafa,
  • Hamad Abdel Hadi,
  • Muna AlMaslamani,
  • Alaaeldin Abdelmajid
Ahmad Al Bishawi
Hamad Medical Corporation
Author Profile
Shiema Abdalla
Hamad Medical Corporation
Author Profile
Marwa Askar
Hamad Medical Corporation
Author Profile
Wael Kanjo
Hamad Medical Corporation
Author Profile
Amal Sameer
Hamad Medical Corporation
Author Profile
Gihan Mustafa
Hamad Medical Corporation
Author Profile
Hamad Abdel Hadi
Hamad Medical Corporation
Author Profile
Muna AlMaslamani
Hamad Medical Corp
Author Profile
Alaaeldin Abdelmajid
Hamad General Hospital
Author Profile

Abstract

Our patient is a 39-year-old male with normal baseline blood parameters who presented with COVID-19 infection, associated with neutropenia and then progressed to critical disease culminating into CSS. Based on risks and benefits evaluation, he was treated with Tocilizumab reinforced with G-CSF leading to full recovery including reversal of neutropenia.
19 Feb 2022Submitted to Clinical Case Reports
21 Feb 2022Submission Checks Completed
21 Feb 2022Assigned to Editor
09 Apr 2022Reviewer(s) Assigned
21 Apr 2022Review(s) Completed, Editorial Evaluation Pending
26 Apr 2022Editorial Decision: Revise Minor
14 May 20221st Revision Received
17 May 2022Submission Checks Completed
17 May 2022Assigned to Editor
17 May 2022Review(s) Completed, Editorial Evaluation Pending
18 May 2022Editorial Decision: Accept